Medical Management of Melanoma

  • Author: Ahmad Tarhini, MD, PhD (More Info)
  • Associate Editor: John M. Kirkwood, MD
  • Editor In Chief: Ramaswamy Govindan, MD
  • Last Reviewed: 7/26/18 (What's New)

Summary

  • FDA expanded the indication of dabrafenib combined with trametinib as adjuvant therapy for patients with melanoma and BRAF V600E or V600K mutations after complete resection
  • COMBI-AD phase III trial showed those receiving dabrafenib plus trametinib vs placebo were 53% less likely of recurrence[Long 2017]

Action required